TORONTO, ONTARIO / CRWEPRESSRELEASE / August 17, 2015 / Theralase Technologies Inc. (“Theralase” or the “Company”) (CVE:TLT) (OTCMKTS:TLTFF), a leading biotechnology manufacturer focused on commercializing medical technologies to eliminate pain and destroy cancer, announced today that it has provided a comprehensive corporate update on a recent radio program entitled The Korelin Economics Report.
These highlights include:
- Status of regulatory approval for next generation therapeutic laser
Status of sales and marketing team for product launch
Revenue expectations post product launch
Full interview available here:
Roger Dumoulin-White, President and CEO, Theralase stated, “Theralase is completing the final steps for commercialization of our next generation therapeutic laser as we await Canadian regulatory approval. Post launch, the Company will be in a position to demonstrate the enhanced efficacy that this next generation technology will bring to the worldwide pain market.”
About Theralase Technologies Inc.
Theralase Technologies Inc. (“Theralase(R)”) (CVE:TLT) (TLTFF: OTC) in its Therapeutic Laser Technology Division designs, manufactures and markets patented super-pulsed laser technology indicated for the: elimination of pain, reduction of inflammation and dramatic acceleration of tissue healing for numerous nerve, muscle and joint conditions. Theralase’s Photo Dynamic Therapy Division researches and develops specially designed molecules called Photo Dynamic Compounds, which are able to localize to cancer cells and then when laser light activated, effectively destroy them.
Theralase Technologies Inc. was recognized as a TSX Venture 50(R) company in 2015. TSX Venture 50 is a trademark of TSX Inc. and is used under license.
This press release contains forward-looking statements, which reflect the Company’s current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.
SOURCE:Theralase Technologies Inc.